Draft Guidance: Topical Dermatologic Corticosteroids: In Vivo Bioequivalence Drug Trials Snapshot: LUNSUMIO-2023/10/25

Draft Guidance: Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities-2023/10/25

Draft Guidance: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers-2023/10/23

Final Guidance: Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol-2023/10/13

Draft Guidance: Diabetic Foot Infections: Developing Drugs for Treatment-2023/10/13

Draft Guidance: Quality Considerations for Topical Ophthalmic Drug Products-2023/10/12

Draft Guidance: Stimulant Use Disorders: Developing Drugs for Treatment-2023/10/04

Final Guidance: Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”-2023/9/29

Draft Guidance: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products-2023/9/21

Draft Guidance: Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications-2023/9/21